Overview

Fluorescent Intra-operative Tumor Margin Examination

Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Tumor margin confirmation is important to confirming appropriate disease excision. Current standard of care is to take select margin samples to pathology for intra-operative readings. However, this is expensive, time consuming, and only assesses the margin contained within the specific sample. In prior work the investigators have determined that indocyanine green (ICG) is highly specific to the tumor bed when injected shortly before surgery. The investigators hypothesize that ICG will be able to accurately identify residual positive tumor margins during sarcoma excision procedures.
Phase:
Phase 2
Details
Lead Sponsor:
Kurt Weiss
Collaborator:
Stryker Nordic